217 related articles for article (PubMed ID: 10382874)
21. In vitro activity of BAY 12-8039, a new fluoroquinolone.
Woodcock JM; Andrews JM; Boswell FJ; Brenwald NP; Wise R
Antimicrob Agents Chemother; 1997 Jan; 41(1):101-6. PubMed ID: 8980763
[TBL] [Abstract][Full Text] [Related]
22. In vitro activity of moxifloxacin against common clinical bacterial isolates in Taiwan.
Sheng WH; Wang JT; Chen YC; Chang SC; Luh KT
J Microbiol Immunol Infect; 2001 Sep; 34(3):178-84. PubMed ID: 11605808
[TBL] [Abstract][Full Text] [Related]
23. Effect of moxifloxacin on bacterial pathogenicity factors in comparison with amoxicillin, clarithromycin and ceftriaxone.
Drago L; De Vecchi E; Nicola L; Tocalli L; Gismondo MR
J Chemother; 2004 Feb; 16(1):30-7. PubMed ID: 15077996
[TBL] [Abstract][Full Text] [Related]
24. [In vitro activity of trovafloxacin in 238 respiratory pathogens].
Alarcón T; Domingo D; Prieto N; Sánchez S; López-Brea M
Rev Esp Quimioter; 1998 Mar; 11(1):47-51. PubMed ID: 9795289
[TBL] [Abstract][Full Text] [Related]
25. In vitro activity of moxifloxacin against recent community-acquired respiratory tract pathogens isolated in France: a national survey.
Decousser JW; Allouch PY; Courvalin P; Leclercq R;
Int J Antimicrob Agents; 2002 Sep; 20(3):186-95. PubMed ID: 12385697
[TBL] [Abstract][Full Text] [Related]
26. In vitro activity of BAY 12-8039, a novel 8-methoxyquinolone, compared to activities of six fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.
Brueggemann AB; Kugler KC; Doern GV
Antimicrob Agents Chemother; 1997 Jul; 41(7):1594-7. PubMed ID: 9210692
[TBL] [Abstract][Full Text] [Related]
27. In vitro activity of moxifloxacin against local bacterial isolates.
Ling ML; Tan PL
Ann Acad Med Singap; 2001 Nov; 30(6):607-10. PubMed ID: 11817288
[TBL] [Abstract][Full Text] [Related]
28. Activity of gatifloxacin and ciprofloxacin in combination with other antimicrobial agents.
Gradelski E; Kolek B; Bonner DP; Valera L; Minassian B; Fung-Tomc J
Int J Antimicrob Agents; 2001 Feb; 17(2):103-7. PubMed ID: 11165113
[TBL] [Abstract][Full Text] [Related]
29. In vitro and in vivo antibacterial activities of DK-507k, a novel fluoroquinolone.
Otani T; Tanaka M; Ito E; Kurosaka Y; Murakami Y; Onodera K; Akasaka T; Sato K
Antimicrob Agents Chemother; 2003 Dec; 47(12):3750-9. PubMed ID: 14638477
[TBL] [Abstract][Full Text] [Related]
30. Antibacterial activity of moxifloxacin (Bay 12-8039) against aerobic clinical isolates, and provisional criteria for disk susceptibility tests.
Barry AL; Fuchs PC; Brown SD
Eur J Clin Microbiol Infect Dis; 1999 Apr; 18(4):305-9. PubMed ID: 10385024
[TBL] [Abstract][Full Text] [Related]
31. In vitro activity of moxifloxacin(BAY 12-8039) against respiratory tract pathogens from six Latin-American countries.
Cardeñosa G O; Soto-Hernández JL
Chemotherapy; 2000; 46(6):379-82. PubMed ID: 11053902
[TBL] [Abstract][Full Text] [Related]
32. Tentative minimum inhibitory concentration and zone diameter breakpoints for moxifloxacin using BSAC criteria.
Andrews JM; Ashby JP; Jevons GM; Wise R
J Antimicrob Chemother; 1999 Dec; 44(6):819-22. PubMed ID: 10590284
[TBL] [Abstract][Full Text] [Related]
33. Pharmacodynamic properties of BAY 12-8039 on gram-positive and gram-negative organisms as demonstrated by studies of time-kill kinetics and postantibiotic effect.
Boswell FJ; Andrews JM; Wise R
Antimicrob Agents Chemother; 1997 Jun; 41(6):1377-9. PubMed ID: 9174203
[TBL] [Abstract][Full Text] [Related]
34. Bactericidal kinetics and postantibiotic effect of sparfloxacin against selected species of respiratory pathogens.
Speciale A; Blandino G; Nicolosi VM; Siracusa V; Caccamo F
J Chemother; 1995 Dec; 7(6):530-4. PubMed ID: 8667038
[TBL] [Abstract][Full Text] [Related]
35. In vitro activity of BAY 12-8039, a new 8-methoxyquinolone.
Dalhoff A; Petersen U; Endermann R
Chemotherapy; 1996; 42(6):410-25. PubMed ID: 8957575
[TBL] [Abstract][Full Text] [Related]
36. Moxifloxacin, a new antibiotic designed to treat community-acquired respiratory tract infections: a review of microbiologic and pharmacokinetic-pharmacodynamic characteristics.
Nightingale CH
Pharmacotherapy; 2000 Mar; 20(3):245-56. PubMed ID: 10730681
[TBL] [Abstract][Full Text] [Related]
37. [Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibiotics (1996)].
Ikemoto H; Watanabe K; Mori T; Igari J; Oguri T; Shimizu Y; Terai T; Inoue H; Nakadate T; Ito C; Yoshida T; Ohno I; Tanno Y; Arakawa M; Igarashi K; Okada M; Ozaki K; Aoki N; Kitamura N; Sekine O; Suzuki Y; Nakata K; Nakatani T; Inagawa H; Kusano N
Jpn J Antibiot; 1998 Jul; 51(7):437-74. PubMed ID: 9755430
[TBL] [Abstract][Full Text] [Related]
38. BAY 12-8039, a novel fluoroquinolone. Activity against important respiratory tract pathogens.
Biedenbach DJ; Barrett MS; Croco MA; Jones RN
Diagn Microbiol Infect Dis; 1998 Sep; 32(1):45-50. PubMed ID: 9791757
[TBL] [Abstract][Full Text] [Related]
39. [In vitro comparative activity of moxifloxacin and other antimicrobials against respiratory pathogens].
Prado V; Giangrieco M; Durán C; Ojeda A; van Flaskamp R
Rev Med Chil; 2000 Dec; 128(12):1319-26. PubMed ID: 11227240
[TBL] [Abstract][Full Text] [Related]
40. Mutant prevention concentrations of ABT-492, levofloxacin, moxifloxacin, and gatifloxacin against three common respiratory pathogens.
Hermsen ED; Hovde LB; Konstantinides GN; Rotschafer JC
Antimicrob Agents Chemother; 2005 Apr; 49(4):1633-5. PubMed ID: 15793158
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
